Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
Ella Day | July 28, 2025 | Appointment | Manufacturing and Production, Research and Development | Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. Based in Sydney, Australia, the affiliate will be led by newly appointed head of commercial, Avendran Naidu, an experienced pharma executive with a background in neuroscience and leadership roles at Jazz Pharmaceuticals, Teva and Ferring.
The Australian arm will commercialise central nervous system (CNS) treatments including Nuvigil (armodafinil) and Modavigil (modafinil) for adults with excessive daytime sleepiness due to narcolepsy. It will also seek to provide rapid patient access to Briumvi (ublituximab), a monoclonal antibody for relapsing-remitting multiple sclerosis, following its recent approval by Australia’s Therapeutic Goods Administration. It has already been approved in the US, EU, UK and Switzerland.
“This is an exciting time for Neuraxpharm Australia as we establish our presence in a new and important market,” said Naidu. “We’re committed to making a meaningful impact in CNS care across Australia.”
CEO Jörg-Thomas Dierks added: “Australia is a key market for Neuraxpharm. Our launch there reflects our mission to expand access to innovative CNS treatments worldwide.”
With this move, Neuraxpharm now operates directly in over 25 countries, continuing its strategy of global growth across key therapeutic areas.
Ella Day
28/7/25
Related Content
MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics …
Sanofi shares results from phase 2 trial for frexalimab in MS treatment
Sanofi has announced new phase 2 trial data for its CD40L monoclonal antibody, frexalimab, for …
